MiMedx Group, Inc. (NASDAQ:MDXG) Shares Acquired by Barclays PLC

Barclays PLC lifted its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 163.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 262,449 shares of the company’s stock after purchasing an additional 163,005 shares during the quarter. Barclays PLC owned about 0.18% of MiMedx Group worth $1,550,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY grew its position in MiMedx Group by 6.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock worth $28,879,000 after purchasing an additional 258,700 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of MiMedx Group by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after buying an additional 92,726 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after buying an additional 413,443 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in shares of MiMedx Group by 299.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after acquiring an additional 770,744 shares during the period. Finally, Royce & Associates LP raised its stake in MiMedx Group by 5.3% in the 3rd quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock worth $5,750,000 after acquiring an additional 48,539 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Trading Up 0.3 %

NASDAQ MDXG opened at $9.42 on Friday. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market capitalization of $1.38 billion, a PE ratio of 17.13 and a beta of 1.97. The company has a fifty day moving average of $8.35 and a 200 day moving average of $7.17.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.